SBC Medical 2026财年第二季度业绩电话会议：增长重新加速，EBITDA增长32%

SBC Medical Group Holdings, Inc.（NASDAQ：SBC）报告称，得益于诊所客流量、客单价及管理服务费的增加，公司2026财年第二季度利润增速快于营收增速。管理层表示，2025年启动的结构性改革已经完成，业务已进入重新加速阶段。

核心要点

• 2026财年第二季度营收同比增长13%至4900万美元，调整后EBITDA增长32%至2000万美元。调整后EBITDA利润率达到41%。
• 截至2026年6月底，SBC共运营287家诊所，同比增加34家。过去12个月的客户就诊人次同比增长10%至692万。
• 年初至今诊所营收增长11%，同店营收增长6%，本季度单次就诊平均消费增长9%。
• 管理层预计，呼叫中心功能的提升以及对Gorilla和Lise诊所支持的加强，按全年计算将带来约1500万美元的额外年费用收入，其中大部分收益将直接转化为利润。
• SBC正在向医美皮肤科、非医美医疗健康、美国及东南亚市场扩展。管理层维持到2035年开设1000家诊所的目标。
• 人工智能仍是增长与成本策略的核心。SBC的目标是在不增加当前间接部门员工人数的情况下，将诊所规模扩大至1000家。

主要财务数据

管理服务收入增加是主要财务驱动因素。该增长反映了2025年6月运营政策变更后积分业务的扩张，以及对某些服务费用的修订。尽管日元走软带来财报折算逆风（因为绝大部分业务以日元结算），SBC仍实现了营收和营业利润的增长。

业务与运营表现

国内诊所增长

管理层将日本市场的改善归因于对营销、价格沟通和面向客户内容的全面改革。SBC审查了其网站、照片、收费结构、社交媒体营销和电视广告，并任命了首任首席营销官。

管理层表示，客户数量和单价目前均在增长。同时指出，在诊所网络、品牌组合、采购规模和数据驱动运营的支持下，SBC医美皮肤科的增速超越了整体市场。

SBC正将“湘南美容皮肤科”更名为“SBC Skin Clinic”，以扩大对寻求基础皮肤科治疗客户的吸引力。公司计划新增两家SBC Skin Clinic、三家Neo Skin Clinic和一家June Clinic。此外，公司还将推出大型脱毛诊所“The Laser”，以及专注于快速男士胡须脱毛的“SBC Men’s Flash”。

非医美医疗健康

非医美医疗健康正被定位为SBC的第二增长引擎。目前交易总额组合中，医美约占84%，非医美约占16%。

SBC于2026年6月组建了专门的非医美团队。该战略将提高现有诊所利用率和收入与以并购为主导的扩张相结合。管理层明确了骨科、眼科、辅助生殖和牙科为其意图拓展的领域。

国际业务扩展

在美国，SBC正在与OrangeTwist展开合作，SBC于2025年12月收购了该公司少数股权。OrangeTwist在6个州拥有24家门店，经常性会员收入占其销售额的40%以上。

两家公司在扩大服务范围的同时，共享采购、营销和运营经验。管理层正研究组合策略，包括新增OrangeTwist门店、开展追加并购、增持股权以及在美国发展SBC品牌业务。

在东南亚，SBC正在采取轻资产模式。在“Powered by SBC”架构下，当地合作伙伴提供资金并运营诊所，而SBC提供采购、标准化、培训和患者引流，以获取与经常性收入挂钩的费用。管理层强调，越南、赴日入境就诊患者以及美国是近期关键的国际增长机会。

人工智能应用部署

SBC正利用26年以上的运营数据开发用于客服、营销、诊所扩张和员工培训的AI工具。已推出的产品包括AI咨询聊天机器人以及旨在支持入境需求的英中口译工具Talk Bridge。

呼叫中心AI计划于2026年期间推出。SBC还在开发用于选址推荐、知识共享、员工培训和个性化客户体验的AI。管理层预计这些工具将提高接听率、减少漏接电话、加速新店开业并抑制固定成本增长。

管理层业绩指引

管理层估计，呼叫中心功能的改善每年可增加约1100万美元，而对Gorilla和Lise诊所的强化支持可增加约400万美元。因此，按全年计算，两者合计的年度效益预计约为1500万美元。

2026财年第二季度仅反映了一小部分。管理层表示，相关服务费用的调整已于6月和7月启动，预计第三和第四季度将带来部分贡献，而完整年度效应预计将从下一财年开始体现。由于这些服务主要由现有固定成本支持，管理层预计绝大部分新增收入将转化为利润。

SBC继续保持到2035年开设1000家诊所的目标。公司还计划在2027年建立长寿医疗中心及线上平台。管理层表示，未来的增长投资将包括有机扩张和有纪律的并购。

风险与关注事项

• 日元走软仍是财报业绩的一大逆风，因为SBC的大部分运营均以日元计价。
• 日本医美市场的竞争一直十分激烈。管理层认为竞争压力可能已经见顶，并预计市场参与者数量将有所减少，但这仍属管理层的研判而非既定的市场结果。
• 第二季度销售及管理费用（SG&A）略有增加，主要是由于二次公开发行产生的一笔一次性费用。管理层表示，该项增加并不代表整体费用呈现上升趋势。
• SBC业务仍高度集中于医美医疗，医美约占其交易总额的84%。公司长期的多元化转型取决于其在非医美医疗及国际市场上的执行情况。

分析师问答集锦

国内业务重新加速增长的驱动因素是什么？管理层归因于重新设计的营销策略、更清晰的价格与客户沟通、新任首席营销官的到位以及对客户满意度数据的深入应用。客户数量与客单价均实现增长。

服务费收入改善的可持续性如何？管理层表示，已确定的1500万美元年增量收益已经落实，且额外成本有限。未来更多高价值服务也有望提高单店平均服务费，不过目前尚未提供具体金额。

SBC将如何在美国市场进行拓展？管理层正在评估多种途径，包括扩张OrangeTwist门店、整合型并购、增持OrangeTwist股份以及开设SBC品牌诊所。

AI的长期定位是什么？SBC旨在利用AI推动营收增长与提升效率。管理层的2035年目标是在不增加现有间接部门员工人数的情况下运营1000家诊所。

长寿医疗将如何实现商业化？SBC正在考虑一种结合诊断、定期健康评估以及个性化疗法或补充剂的模式。管理层计划于2027年建立长寿医疗中心及线上平台。

业绩电话会议完整文字实录

---

完整财报电话会议逐字稿

管理层陈述

Operator

Welcome to SBC Medical Holdings Second Quarter 2026 Earnings Conference Call. Joining me on the call today are Yoshiyuki Aikawa, CEO; and Yuya Yoshida, CFO, COO and AI Evangelist. I am Fukui, Head of IR Department, and I will be your moderator today. Presentation materials for today are posted on our Investor Relations website. Minutes of the call will also be posted as soon as they are prepared.

Today's discussion contains forward-looking statements. These forward-looking statements do not guarantee the future performance. Actual results may change due to various factors. For details, please refer to our filings with the SEC. Today's discussion may also refer to non-GAAP financial indicators. A reconciliation of GAAP to non-GAAP financial measures can be found on our presentation material for today, and we introduce the program today.

First, around 10 minutes of presentation will be delivered using AI. Please rest assured since the content has been reviewed beforehand. Then there will be a message from Dr. Aikawa before we move on to the Q&A session. [Operator Instructions]

We will now start the presentation.

Yuya Yoshida

Thank you for taking the time to join the Second Quarter 2026 Conference Call of SBC Medical Group Holdings, Inc. I will now walk you through our results for the second quarter of 2026, and update on our business strategies and our capital and IR strategy. If I had to sum up this quarter in a single sentence, it is the quarter in which we completed the structural reforms we undertook in 2025, and SBC's growth entered a phase of reacceleration. On the back of an expanding business base and more sophisticated support functions, including AI, we delivered profit growth that outpaced revenue growth.

Let me begin with the clinic highlights. As of the end of June 2026, our number of locations reached 287, up 34 year-on-year. And the annual number of customer visits over the trailing 12 months was 6.92 million, up 10%. Year-to-date clinic revenue rose 11%. Same clinic revenue was up 6% and average spend per visit in the quarter increased 9%. With both customer volume and unit price rising together, our clinic business is showing renewed strength.

Next, our financial highlights. Second quarter revenue was $49 million, up 13% year-on-year. Adjusted EBITDA was $20 million, up 32% and our adjusted EBITDA margin was 41%. Profit growth outpaced revenue growth with profitability improving. In the second quarter, we grew both revenue and profit despite a weaker yen. Because most of our business is conducted in yen, a weaker yen is a headwind for our reported results. Even so, we absorbed it and still delivered strong revenue and operating income. The main driver was higher management services revenue, reflecting the expansion of the points business following the change in our operating policy in June 2025. A revision of certain service fees also contributed.

Now to our strategy update. Our strategy is unchanged. We aim to be a health care platform that supports longevity, people living young and vigorous lives from 2 sides: aesthetic medicine, an appearance-based approach; and non-aesthetic or general medicine, a function-based approach. Our goal is to become the name that comes to mind when people in Japan think of longevity. We believe 4 growth strategies will get us there, accelerating our multi-brand strategy in aesthetic dermatology, expanding our non-aesthetic business, expanding globally and strengthening our competitiveness and reforming our cost structure through AI. I will briefly comment on each of these 4 growth strategies.

We believe that AI is developing into a source of SBC's next competitive advantage. In aesthetic dermatology, we are accelerating our multi-brand strategy to capture increasingly diverse needs and raise lifetime value. First half transaction value grew a strong 19% year-on-year. To reach the customer segment that prefers basic dermatological treatments, which is driving market expansion, we are renaming Shonan Aesthetic Dermatology to SBC Skin Clinic. The skin clinic name lowers the barrier to aesthetic medicine and broadens our appeal, and we will open 2 additional clinics.

Next are our high-value brands for beauty-conscious customers who choose based on the expertise of doctors and equipment. We will add 3 Neo skin clinic locations for a total of 4 and 1 June clinic for a total of 7. And to meet solid demand in men's aesthetics and hair removal, we are launching 2 new formats, the laser, a large-scale hair removal clinic; and SBC Men's Flash, which specializes in men's beard removal with high-speed operations. Gorilla Clinics' first half transaction value was $62 million, up 19% year-on-year. Using hair removal and oral AGA treatments as entry points, we guide customers step-by-step towards dermatological and higher-value treatments, and this deeper penetration of our existing customer base drove the growth.

Aiming for a Japan where longevity means SBC, we position non-aesthetic health care as our second growth engine. Our transaction value mix is still roughly 84% aesthetic and 16% nonaesthetic, which means the potential upside is significant. To drive this, we established a dedicated team in June 2026, led by Naoya Fujimoto, formerly an Executive Officer at a major health care and IT talent platform company. We will strengthen both customer acquisition and medical management. First, sharpening the acquisition and operations of existing clinics to raise utilization and revenue per clinic and in parallel, using M&A to expand the number of locations.

The premise of our global expansion is a stable earnings base in Japan. On that foundation, we grow overseas with discipline. In the United States, we are advancing our collaboration with OrangeTwist, in which we took a minority stake in December 2025. OrangeTwist has 24 locations across 6 states and a membership base where recurring revenue exceeds 40% of sales. We are currently sharing operating know-how and expanding the service menu. And over the medium to long term, we aim to export the model we established in the United States to Japan and Asia.

In Southeast Asia, we are exporting asset-light, the operating system honed in Japan, affordable, reliable and standardized. We are proving this out at our first Thai clinic, BLEZ Clinic. Under our powered by SBC model, the local partner provides capital and operations, while SBC supplies procurement, standardization, training and patient acquisition, earning recurring fees linked to revenue in return. This expands our footprint at a high return on invested capital, or ROIC, while holding down capital expenditure. Starting from Thailand, we will expand the model across [indiscernible].

AI is a foundational strategy supporting both growth and efficiency. We are leveraging more than 26 years of accumulated management data to support AI development, building a barrier that is hard to replicate. Strengthening our MSO platform through AI lifts growth in 3 directions at once, the number of locations, the fee per clinic and the range of service menus. A more attractive platform draws in new clinics, more active transactions raise service fee levels and the service menu expands, a virtuous cycle that we believe drives recurring consolidated revenue and EPS growth. We are progressively deploying AI that directly supports clinic management.

Our AI chatbot for round-the-clock inquiries and our AI interpreter, Talk Bridge, which gives on-the-spot English and Chinese interpretation to capture inbound demand are already released. Our marketing AI is rolling out in phases and a call center AI to raise answer rates and prevent missed calls is scheduled for release during 2026. Together, these enhance the customer experience and our marketing, contributing to higher clinic revenue.

We are also deploying AI that supports network expansion itself, a site candidate recommendation AI that gathers population, foot traffic and competitor data to speed up site selection and a knowledge sharing AI that turns 26 years of on-the-ground know-how into a company-wide asset, improving the repeatability of new openings and helping staff ramp up quickly. This lets us expand the network with both precision and speed while maintaining high quality and strengthens our appeal as a franchise. More sophisticated support functions, AI foremost among them, translate directly into greater value for clinics, and we are raising service fee levels in stages accordingly.

Enhanced call center functions are expected to add roughly $11 million per year and stronger support for the Gorilla and Lise clinics is expected to add roughly $4 million, together about $15 million per year on a full year basis. On a win-win basis with the medical corporations, we aim to sustainably raise our average fee per clinic, or AFTC, at limited additional cost, which further supports profitability. Since our NASDAQ listing, we have reinforced our core platform and laid strategic groundwork overseas and in new domains.

From here, we enter a phase of multifaceted acceleration, expanding and rebranding domestic aesthetic dermatology, launching new formats, strengthening non-aesthetic health care, moving the United States into Phase II, expanding B2B and joint ventures in Southeast Asia, applying AI and planning a longevity center for 2027. Through disciplined investment, we will pursue differentiated earnings and sustained EPS growth.

Finally, our capital and IR strategy. Our basic policy is to pursue EPS growth and a normalization of our valuation in parallel, enhancing shareholder value over the medium to long term. Backed by ample cash, we are investing in both organic growth and disciplined M&A. At the same time, we recognize that SBC's recognition in the capital markets, particularly in the United States, is still limited. That said, our investor base is broadening rapidly. Our shareholder base has grown roughly 4.7x year-on-year as of July 2026.

Building on this momentum, in 2026, we have and will continue to actively participate in IR conferences in New York, Hong Kong and elsewhere and step up our year-round investor engagement, including NDRs, one-on-ones and outreach to retail investors. We will also keep working to expand analyst coverage. Through all of this, with continuous EPS growth and the pursuit of an appropriate valuation in the capital markets as our 2 wheels, we expect to deliver even greater value to all our stakeholders, beginning with you, our shareholders. We hope you will look forward to what lies ahead for SBC.

That concludes my remarks. Thank you very much for your attention.

Hikaru Fukui

Thank you for watching. I will now turn the call over to Dr. Aikawa, CEO, to deliver a short speech.

Yoshiyuki Aikawa

Good evening. I am Aikawa, CEO of SBC Medical Group Holdings. Just as you have seen in the presentation, the second quarter numbers were very strong numbers. In 2024 and in 2025, in these 2 years, we saw a dramatic change in aesthetic medicine environment in Japan, where competition became very fierce.

It is now the 26th year after we started our business. And the growth was somewhat stagnant. But in the last 2 years, in the much changed environment, how do we accelerate our growth was what we put our focus on and put our efforts on marketing methods and feed the treatment, these were all renewed. And in such an environment, we were able to demonstrate that we can achieve strong growth. We are determined to continue this strong growth.

Continuing from this second quarter, amongst Japanese medical institutions, we are going to be the organization that makes the most use of AI. Our COO is taking a leadership on that. AI-based chat to respond to patients automatically is one example or AI telephone response appointment system, recommendation functions. We are able to use AI for various functions to improve convenience for our customers and improve customer experience. And at the same time, we will be able to improve the efficiency of our management. we will have more efficient management. And I'm sure that, that will contribute to profitability. That is how we foresee.

We aim to be longevity company. That is the company-wide objective. The growth was primarily driven in aesthetic health care, but including orthopedic and ophthalmology, fertility treatment. In these categories, we expect to see growth, and we intend to achieve growth in these categories. Right now, the majority of our business is aesthetic health care. But in 10 years' time, the proportion of aesthetic health care is expected to be smaller, while other categories will be much larger in proportion in terms of financial performance and profitability. That is the future that we are envisioning and targeting.

As for the number of clinics, it is now close to 300. And in 2035, our target is to have 1,000 clinics. And we would like to be able to achieve that target as soon as possible. And therefore, we would like to achieve growth in categories other than aesthetic health care. And as for international business, we have clinics in Thailand, Singapore and Vietnam. And gradually, business is expanding. And when we have one winning pattern, we will be able to roll that out in the all of the Asian region.

This second quarter was a very strong quarter, and I believe that we were able to meet the expectations of the investors and we will work to improve upon the results in the third and the fourth quarters to meet your expectations. Thank you.

Hikaru Fukui

That was Aikawa. Thank you very much. Now we would like to open the floor for Q&A session. [Operator Instructions] Now the first question, reaccelerating the growth that was presented. domestic, the aesthetic clinics performance is improving compared to the first half of 2024 and '25, what structural changes have been brought about? Can we expect to see further improvement going forward?

Yoshiyuki Aikawa

I would like to respond to that question. Competitive landscape has become more fiercely competitive. And what I have done is to look at the results of customer satisfaction survey and to see where we have competitive edge or where we are weaker competitively, we have conducted such analysis. and we are sending out information from our website using various media, including photographs, fee structure and expressions, all of these were reviewed and renewed.

First CMO, the Chief of Marketing, was newly appointed. That was also a major change. And in marketing, social media marketing, TV commercials, we have reviewed all of these thoroughly so that we are able to win in this very competitive environment. And now we are seeing good results. And I believe this momentum will continue, and I expect strong growth to continue.

Yuya Yoshida

I would like to add to that. As Dr. Aikawa explained, we are seeing results in terms of number of customers and unit price, both are growing. And that is the difference between the past 2 years. And in aesthetic dermatology, our growth is outpacing the market growth. So it is not merely because the market itself is growing, but our SBC platform is stronger as a result of revamping, including of marketing. And as a result, we have become stronger, and we are becoming more confident.

Hikaru Fukui

Moving on to the next question, question on Japan. What is the competitive environment in Japanese aesthetic health care market?

Yoshiyuki Aikawa

Well, in terms of the competitive landscape, at maximum, last year or in the first half of this year, right now, has probably seen the peak of competition. And recently, or earlier, there were a lot of new aesthetic clinics being opened increasing their numbers. But recently, we have seen slowing down of the increase. So the players -- the number of players is going to be reduced going forward. But in the Japan's aesthetic medicine market, I believe that the market itself is going to expand going forward with the expansion of the market, but slightly reduced number of players in the market, that is what we are expecting to see. And going forward, we believe that the environment will come where we will be able to exhibit our strength.

Yuya Yoshida

If I may add, as Dr. Aikawa mentioned, regarding the competitive landscape, I believe that there has been a complete change of the current SBC's position has been further strengthened. that means that we are currently in a favorable position for SBC in terms of the number of locations and the customer volume, and we are positioned as #1 overwhelmingly with a very overwhelmingly stronger brand power and also business base and the scale of the business. In each of our brands, we are able to provide value as well as the balanced pricing and values. Therefore, that will prevent us from being falling into the competition in pricing.

While we are able to maintain our competitiveness, we will be able to maintain profitability. And it is something that cannot be done by any other peers who are running single brand. And given the current environment where the environment for business running for other peers are getting difficult and considering the current longevity trend, we are going to grow further. In that landscape, we believe that SBC will be able to increase our share of market.

If I may be more specific, for example, aesthetic dermatology area, utilizing our financial capability, we are able to buy the cutting-edge medical equipment at scale faster than any other players. And also furthermore, we are going to optimize our operation utilizing our AI capability. CapEx or whatever which will require investment can be done. including these strategies, we believe that this is something that cannot be reproduced by any other peers.

And when it comes to the data foundation being improved, as Dr. Aikawa mentioned, the management reform is based upon the data-driven matter based upon the specific analysis of the data, we are trying to enhance our business base. And I believe that we have been able to strengthen our business base further. We are increasingly confident.

Hikaru Fukui

Next question is about financials. The second quarter was a very great quarter. However, SG&A was higher than expected. [ We will please detail ].

Yuya Yoshida

I would like to respond to that question. Thank you very much for commending us for having a great quarter. As for SG&A, it increased slightly. But what is important first is that it was only a slight increase. There are some reasons. One of the reasons is onetime cost as a result of the secondary offering that accounted for much of the increase. It is not that overall trend is that of increasing SG&A.

Hikaru Fukui

We have another question on finance. About $15 million of upside in fee was highlighted. What is the timing of those increases? And how much of this is already reflected in Q2? And what is the incremental margin contributions?

Yuya Yoshida

Let me respond to this question again. Regarding the time line, it will depend on each item, but there are specifically 2 items, Gorilla Clinic starting from July and call center revision starting from June. Sorry, call center starting from July, Gorilla Ray Clinic from -- starting from June. So regarding the results under review for the second quarter, which did not include this impact, some of which may have been included in the results for June. Part of the impact has been included slightly in the results under review.

So full contribution will be seen starting from next fiscal year. But in Q3 and Q4 for this fiscal year, about half of the unrealized gains will be included. These 2 items that we are explaining have been already determined. But other than this, high value-added services will contribute to the further increase in the unit price. Revenue per clinic will be further enhanced by other factors than what is described here.

Regarding the contribution to the profitability, in principle, these are the services which are provided based upon the fixed cost. Therefore, most of the gains can be directly contributing to the profits. So what has been determined is the basis for the upside in the amount of $15 million. We are increasingly confident in achieving this. Thank you very much.

Hikaru Fukui

Next is about global strategy. OrangeTwist, what is the current status of the OrangeTwist? Could you please give us your update? Since you made investment, what learnings did you get? Or in the coming 12 months, what kind of important milestone are you planning to have?

Yuya Yoshida

Since I'm responsible for international business, I would like to respond to this question. As for major learning in the past 6 months or so, the management structure was reviewed and the -- one of the co-founder became the CEO. He's [indiscernible], and we have learned much from him. MedSpa business in the U.S., how it will be expanded in the United States, we are learning that under his leadership. For example, SBCs procurement can be utilized to reduce cost of purchase, comprehensive marketing strategy is also being revisited.

In actual clinics, customer proposition, protocol is being reviewed and events to attract customers will be organized. This is related to branding. We have not done these before. But in a very short period of time, these are implemented one after another. The speed of implementation is much quicker after Quint joined.

In the growth area, longevity, longevity products will be enhanced in conjunction with SBC. In the next 12 months, what we can expect over the next 12 months? Well, SBC is working together with OrangeTwist. And under SBC brand, we would also like to do business in the United States under our own brand. And we believe that there is a synergy between OrangeTwist and SBC.

Yoshiyuki Aikawa

I would also like to add to that. I agree fully with what Yoshida-san said. After the leadership change, there has been a rapid reform of Orange Trust, which is reflected in the performance. And we have much to learn from his leadership, and he visited Japan, Flint visited Japan, and he also served our clinics here in Japan. We were able to provide information from our side, and we had a lot to learn from the U.S. It may take time, but we would like to make sure that we make the full use of these opportunities and learn and to build a strong business model in the United States.

Hikaru Fukui

Thank you. We have another question on the United States. In expanding U.S. business, what are you thinking of doing? Will you explain OrangeTwist locations or buy other companies or increase your ownership of OrangeTwist?

Unknown Executive

Well, expanding OrangeTwist itself, yes, this is something that we are sure will be done and increasing our stake in the OrangeTwist is also being considered. And members of the OrangeTwist will be cooperating with us so that our unique model, winning model in the United States market, together with them, we would like to scale across regions or increasing the number of locations. If I may add, as he mentioned, in principle, there will be a mixture of different measures.

As SBC, we may be deploying our locations as well. In principle, Orange Taste rollup strategy, M&A being utilized in order to increase the clinics. And last year, we did one and increasing the number of locations reaching 24 now. Other than this, there may be opportunities for M&A. There has been approach to Orange Toast. Therefore, we are currently considering all of these as the opportunities for growth. Thank you very much for your question.

Hikaru Fukui

Next question is about Southeast Asia. Your strategy in this region, what is the traction of the strategy being implemented? What are going to be the future steps?

Unknown Executive

In Vietnam, in Thailand and in Singapore, we have clinics. In Singapore, last year, we acquired AHH. We would like to expand AHH clinics in Singapore. As for Vietnam, it has been already 10 years after we have started operating clinics. And for the first time, we are seeing increase in the number of Vietnese patients, customers, and it has started to grow rapidly. Once we have a strong model here, then in Vietnam alone, population is 100 million. So I'm sure we will be able to open other locations. In Thailand and Hong Kong, these are countries where there are people who like Japanese culture, and I believe it will be easier to open clinics in these countries. in relation to international business.

As for inbound on a single month basis, in the past few months, we have seen growth by several folds. And in particular, we have seen increase in customers from Taiwan. The measures that we have implemented in the past 1 or 2 years are leading to the actual results in our business in Asia and also our business with inbound customers. Thank you very much.

Hikaru Fukui

We have a related question. Outside of Japan, in the second half of 2026 and in 2027, in that time span, what territories represent the greatest growth opportunity?

Unknown Executive

Well, as we mentioned earlier, Vietnam may have the opportunities and also inbound market, foreign visitors coming to Japan. This market is growing for sure. And business in the U.S. with the leadership change, it is showing a speedy growth. So these 3 areas are the -- those opportunities that we will be growing for sure.

Hikaru Fukui

Next question is about AI strategy. Service fee is going to be enhanced due to the development of AI technologies. And other than this, what kind of impacts can be seen from the implementation of AI technologies? If you have any time scale for that, could you please share it with us?

Yuya Yoshida

I'm happy to address that question. We are releasing various AI products one after another. As Dr. Aikawa explained, chatbot has been released in August. And before the end of the year, we expect to open AI call center and AI preceptor to support the training of nurse concierge will also be launched. So in the next 6 months to 12 months, we will be introducing more AI products and core system will be revamped using AI. What we are basically aiming to achieve is that in 2035, we would like to have 1,000 clinics, at least in the indirect department, we would like to maintain the scale at the current scale in terms of headcount, and we would like to achieve 1,000 clinics without increasing fixed cost.

To improve operational efficiency, we are using AI and that effort is moving ahead of other areas, but we would like to improve customer experience. For example, AI chatbot released on the web sites may be converted to apps so that treatment history and simulation using customized on photographs may be used in more personalized fashion to improve UX. Through such efforts, we would like to improve customers' convenience and improve our sales. We not only aim to improve efficiency, but increase sales through the use of AI. That is what we are hoping to achieve, and we expect to achieve.

Hikaru Fukui

Thank you. We have a question on longevity about longevity efforts. How does SBC longevity as an opportunity? And how does SBC plan to make it a business?

Yuya Yoshida

Yes, longevity in Japan. Japan is actually the country where people live longest with the aging population in this country. and the number of elderly people is very large. So compared to other countries, in this sense, we are more advanced. We would like to turn this into a major pillar for profitability and revenue for health care. Logically speaking, and simply put, for people to live healthy and vibrant lives for long so that they are able to enjoy their lives, we would like to help that through implementation of our medical technologies.

So in that sense, aesthetic medicine or health care is helpful for -- even for those elderly people in order to better their appearance. -- by doing so, they will be able to stay vibrant and they will be able to continue working. So that we really -- we believe that we will be able to help people living that way. And for example, regenerative medicine and orthopedics that we are engaged in, in these areas, if you have a painful knee or joint, you are not able to enjoy playing sports or you're not able to travel. So in these senses, in order to prevent such restriction of activities for such people, we would like to help them.

And in dentistry, chewing, utilizing your own teeth to eat, is very important for human activity. So we'd like to grow that area as well. And the gene screening that is conducted in the United States in order to see the ages of organs can be investigated for which peptides or hormone endocrinology and supplements, any kinds of therapies can be proposed to address such aging of organs, kind of subscription recurring services based upon the investigation of the cell age on a regular basis and also providing the health checkup and whatever necessary for that particular person through supplemental provision, that kind of business model is being considered by us.

Unknown Executive

If I may add, there are 2 major points, SBC's positioning. related to what he mentioned earlier. In medical areas, we are able to provide layers of intervention. We are not just showing the numbers. We are able to provide improvement through therapies. We are able to provide such medical things or services. That is the differentiator from others. And the second point is the healthy longevity for people to live lively and vibrant lives, which will lead to the expansion of the aesthetic market. And in this area, which is the area where SBC is able to grow further.

So for longevity trend to continue for medium to longer term, will provide the tailwind for us strongly. And next year, we are going to establish the longevity center and online platform will be built next year. So we'd like to make the branding where people will associate longevity always with SBC in Japan.

Hikaru Fukui

Regarding the next question about the capital, net cash is almost 45% of market cap. Net cash is increasing as such. So with such ample cash on hand, what plans do you have in order to enhance shareholder values? For investors, why do we need to pay attention to SBC now?

Yuya Yoshida

First of all, before we became public under our group, we have Ray Clinics and Gorilla clinics. In the beginning, when we acquired these clinics, total turnover was about JPY 25 billion. But in the last 3 to 4 years, it has increased to JPY 33 billion or to over JPY 30 billion level. So growth was achieved. Going forward, orthopedics, ophthalmology and also aesthetic health care in these categories, we would like to implement M&A so that we can achieve 1,000 clinics in 2035. We want to realize this and that end up just having a pie in the sky. We aim to achieve this number by 2035.

Hikaru Fukui

Are there any other questions? Then with this, we would like to conclude the Q&A session. Lastly, we would like to invite CFO, Yoshida, to say a few words to close. CFO, Yoshida, please have the floor.

Yuya Yoshida

Thank you very much for participating in our conference call -- earnings call out of your busy schedule. As you have seen today, we are glad as CFO to be able to deliver and report this strong results for the quarter under review. We are confident in accelerating our growth. And as we have been making over the past several years, we have been able to strengthen further this positioning of SBC. As a result of this, the service unit price or fee has been enhanced for clinics. And by developing the new business format, we'll be able to increase the clinic network. And for the further growth in the medium to longer term, we'll be able to implement AI and longevity trend, which will all further strengthen positioning of SBC. Please stay tuned in what we are able to bring.